<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634647</url>
  </required_header>
  <id_info>
    <org_study_id>080074</org_study_id>
    <secondary_id>08-C-0074</secondary_id>
    <nct_id>NCT00634647</nct_id>
  </id_info>
  <brief_title>Satraplatin and Prednisone to Treat Prostate Cancer</brief_title>
  <official_title>A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Satraplatin is an experimental drug that may be of benefit to patients with prostate cancer.&#xD;
&#xD;
      Prednisone is approved for treating prostate cancer.&#xD;
&#xD;
      The gene excision repair cross-complementing rodent repair deficiency complementation group 1&#xD;
      (ERCC1) helps repair cell damage caused by satraplatin. It is possible that patients who have&#xD;
      a variant of this gene will not benefit from treatment with satraplatin because the drug will&#xD;
      not be able to damage the cancer cells effectively.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To determine if satraplatin may help treat prostate cancer in patients with certain variants&#xD;
      of the ERCC1 gene.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients with advanced androgen-independent prostate cancer whose disease has not responded&#xD;
      to hormonal therapy or at least one type of chemotherapy and whose x-rays, scans or other&#xD;
      tests have shown their cancer to be spreading.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants have a blood test to determine if they have a variant of the ERCC1 gene.&#xD;
&#xD;
      Participants take satraplatin by mouth every day for 5 consecutive days out of every 35 days&#xD;
      and prednisone by mouth every day. These 35-day treatment cycles may continue for 6 months or&#xD;
      longer, depending on the benefits and side effects of the treatment.&#xD;
&#xD;
      During the treatment period, patients undergo the following tests and procedures:&#xD;
&#xD;
        -  Blood tests on days 1 of the treatment cycle.&#xD;
&#xD;
        -  Weekly blood draws for the first 3 treatment cycles.&#xD;
&#xD;
        -  Imaging studies (e.g., bone scans, computed tomography (CT) scans) every two cycles to&#xD;
           determine the response to treatment.&#xD;
&#xD;
        -  Surgical or medical suppression of testosterone in patients whose cancer cells continue&#xD;
           to grow due to exposure to the hormone....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Satraplatin is an oral, third-generation platinum analog that has recently been shown to&#xD;
           increase prostatic specific antigen (PSA) decline rates and progression-free survival in&#xD;
           hormone-resistant prostate cancer.&#xD;
&#xD;
        -  Satraplatin acts by binding to deoxyribonucleic acid (DNA) forming intra- and&#xD;
           interstrand cross links (DNA adducts), resulting in cell-cycle arrest in G2 phase and&#xD;
           eventual apoptosis. One of the mechanisms that bring about resistance to platinum-based&#xD;
           chemotherapy is removal of the platinum-DNA adducts by DNA repair pathways, called&#xD;
           nucleotide excision repair (NER) and base excision repair (BER) pathways.&#xD;
&#xD;
        -  Polymorphisms in the DNA repair genes causing impaired NER and BER capability has&#xD;
           recently been shown in some cancers, including head and neck squamous cell carcinoma,&#xD;
           non-small cell lung carcinoma, and ovarian carcinoma to predict better treatment outcome&#xD;
           and response to platinum treatment.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Primary objective of this single arm study is to determine if the presence of ERCC1&#xD;
           variant gene polymorphism which is involved with DNA damage repair may be associated&#xD;
           with an impact on the progression-free survival of patients with metastatic prostate&#xD;
           cancer.&#xD;
&#xD;
        -  Secondary objectives of this study includes demonstration of biologic effect by the drug&#xD;
           satraplatin in the patient and in the tumor whenever possible, by obtaining tissue&#xD;
           biopsy and white blood cell collections, to determine correlation of biologic or&#xD;
           clinical effects with PSA progression, evaluate correlations between genotype&#xD;
           expression, repair pathways and clinical events, and obtain laboratory correlates which&#xD;
           will include pharmacogenetic analysis of prostate cancer patients with genotyping using&#xD;
           Polymerase chain reaction (PCR) followed by either restriction fragment length&#xD;
           polymorphism or direct sequencing to genotype single nucleotide polymorphisms of ERCC1,&#xD;
           x-ray repair cross-complementing protein 1 (XRCC1), and poly (ADP-ribose) polymerase 1&#xD;
           (PARP1).&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Patients with metastatic androgen-independent prostate cancer.&#xD;
&#xD;
        -  Had docetaxel-based chemotherapy, but no more than 1 previous cytotoxic chemotherapy&#xD;
           line.&#xD;
&#xD;
        -  Good organ function.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Phase II trial with single stage design and a planned accrual of 66 patients.&#xD;
&#xD;
        -  Progression-free survival will be determined using a Fisher's exact test.&#xD;
&#xD;
        -  Will treat all enrolled patients with oral satraplatin 80 mg/m^2 dose on days 1-5 of&#xD;
           every 35-days cycle plus Prednisone 5 mg twice daily every 35 days.&#xD;
&#xD;
        -  Genotyping will be performed after the first 20 patients to determine if the proportion&#xD;
           for wild-type ERCC1 and variants follow a 20:80 split.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2008</start_date>
  <completion_date type="Actual">May 1, 2012</completion_date>
  <primary_completion_date type="Actual">February 1, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival.</measure>
    <time_frame>15 months</time_frame>
    <description>Time between the start of therapy and progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progressive Disease is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 57 months.</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>time between the first day of treatment to the day of death, approximately 15.7 months</time_frame>
    <description>Overall Survival is the time between the first day of treatment to the day of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Genetic Polymorphism</condition>
  <arm_group>
    <arm_group_label>Satraplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satraplatin</intervention_name>
    <description>80 mg/m^2 days 1-5 of every 35 day cycle</description>
    <arm_group_label>Satraplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>5 mg twice daily every 35 days</description>
    <arm_group_label>Satraplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        A. Patients must have histopathological confirmation of prostate cancer by the Laboratory&#xD;
        of Pathology of the National Cancer Institute (NCI) or Pathology Department of the National&#xD;
        Naval Medical Center or Walter Reed Army Medical Center prior to entering this study.&#xD;
        Patients whose pathology specimens are not available may be enrolled in the trial if the&#xD;
        patient has a clinical course consistent with prostate cancer and available documentation&#xD;
        from an outside pathology laboratory of the diagnosis. In cases where original tissue&#xD;
        blocks or archival biopsy material is available, all efforts should be made to have the&#xD;
        material forwarded to the research team for use in correlative studies.&#xD;
&#xD;
        B. Patients must have metastatic progressive androgen-independent prostate cancer. There&#xD;
        must be radiographic evidence of disease (by computed tomography (CT) scan or bone scan)&#xD;
        after primary treatment that has continued to progress despite hormonal agents. Progression&#xD;
        requires that a measurable lesion is expanding, new lesions have appeared, and/or that&#xD;
        prostatic specific antigen (PSA) is continuing to rise on successive measurements. Patients&#xD;
        must have progressive disease after receiving 1 prior docetaxel-based cytotoxic&#xD;
        chemotherapy. Patients on flutamide for the prior 6 months must have disease progression at&#xD;
        least 4 weeks after withdrawal. Patients on bicalutamide or nilutamide must have&#xD;
        progression at least 6 weeks after withdrawal.&#xD;
&#xD;
        C. Patients may only have received 1 prior cytotoxic chemotherapy. For the purpose of this&#xD;
        study, multiple courses of a taxane-based regimen may count as a single regimen. Multiple&#xD;
        courses of a non-taxane agent or a combination chemotherapy regimen, administered in a&#xD;
        similar fashion may count as a single regimen.&#xD;
&#xD;
        D. Patients must have a life expectancy of more than 3 months.&#xD;
&#xD;
        E. Patients must have a performance status of 0 to 2 according to the Eastern Cooperative&#xD;
        Oncology Group (ECOG) criteria.&#xD;
&#xD;
        F. Patients must have adequate organ function as defined below:&#xD;
&#xD;
        Leukocytes greater than or equal to 3,000/microl.&#xD;
&#xD;
        Absolute Neutrophil Count greater than or equal to 1,500/microl.&#xD;
&#xD;
        Platelets greater than or equal to 100,000/microl.&#xD;
&#xD;
        Total bilirubin less than or equal to 1.5 times institutional upper limits of normal&#xD;
        (Except patients with Gilbert's disease who may proceed despite elevated total bilirubin).&#xD;
&#xD;
        Aspartate aminotransferase (AST)serum glutamic oxaloacetic transaminase(SGOT) and alanine&#xD;
        aminotransferase (ALT)serum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5&#xD;
        times institutional upper limit of normal&#xD;
&#xD;
        Creatinine less than or equal to 1.5 times institutional upper limits of normal.&#xD;
&#xD;
        OR&#xD;
&#xD;
        Creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with&#xD;
        creatinine levels above institutional normal.&#xD;
&#xD;
        G. Patients must have recovered from any acute toxicity related to prior therapy, including&#xD;
        surgery. Toxicity should be &lt;= grade 1 or returned to baseline.&#xD;
&#xD;
        H. Hormonal profile: all patients who have not undergone bilateral surgical castration must&#xD;
        continue suppression of testosterone production by appropriate usage of gonadotropin&#xD;
        releasing hormone (GnRH) agonists.&#xD;
&#xD;
        I. Patients must not have any ongoing malignancies requiring active therapy.&#xD;
&#xD;
        J. Patients must be able to understand and sign an informed consent form.&#xD;
&#xD;
        K. Concurrent use of bisphosphonates will be allowed if patients have previously been on&#xD;
        it; if patients are not on bisphosphonates at the time of study enrollment, bisphosphonates&#xD;
        may be started at cycle 2.&#xD;
&#xD;
        L. Patients who require hematopoietic growth factor support (e.g. epogen, darbepoetin), but&#xD;
        not myeloid growth factors (except after cycle 1 day 1 if clinically indicated),&#xD;
        non-steroidal anti-inflammatory drug (NSAIDs), and other maintenance medications prior to&#xD;
        study entry will be allowed to continue their supportive therapies.&#xD;
&#xD;
        M. Results from embryo-fetal development indicated that satraplatin should be considered a&#xD;
        teratogen in women of childbearing potential and hazardous in respect to spermatogenesis&#xD;
        for men. For this reason, men must agree to use adequate contraception (abstinence;&#xD;
        hormonal or barrier method of birth control) prior to study entry and for the duration of&#xD;
        study participation.&#xD;
&#xD;
        N. Patients must be able to swallow capsules.&#xD;
&#xD;
        O. Patients on chronic stable steroids (equivalent to no more than 10 mg of prednisone&#xD;
        daily dose) used for non-cancer treatment may be allowed on study.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        A. Patients who have had prior treatment with satraplatin or other platinum containing&#xD;
        compounds will be excluded.&#xD;
&#xD;
        B. Patients may not be receiving any other investigational agents.&#xD;
&#xD;
        C. Patients with known active brain metastases are excluded from this clinical trial&#xD;
        because of their poor prognosis and because they often develop progressive neurologic&#xD;
        dysfunction that would confound the evaluation of neurologic and other adverse events.&#xD;
&#xD;
        D. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
        composition to satraplatin or prednisone.&#xD;
&#xD;
        E. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
        serious infection, symptomatic congestive heart failure, unstable angina pectoris, or&#xD;
        psychiatric illness/social situations that would limit patient compliance with study&#xD;
        requirements.&#xD;
&#xD;
        F. Prior radiation therapy to greater than 30 percent of the bone marrow, or who have&#xD;
        received strontium-89, rhenium-186, or rhenium-188 will be excluded from this trial.&#xD;
        Patients who have received prior radiotherapy must have recovered from acute toxicity due&#xD;
        to radiation. Patients who have received samarium-153 are eligible for the study because&#xD;
        samarium has a significantly reduced half-life compared to aforementioned isotopes.&#xD;
&#xD;
        G. Patients with immune deficiency are at increased risk of lethal infections when treated&#xD;
        with marrow-suppressive therapy. Therefore, human immunodeficiency virus (HIV)-positive&#xD;
        patients are excluded from the study.&#xD;
&#xD;
        H. Patients with a history of major gastrointestinal surgery or pathology likely to&#xD;
        influence absorption of oral medications, like bypass surgeries, Whipple's procedure, or&#xD;
        any surgery that would impair reliable absorption of oral drugs.&#xD;
&#xD;
        I. Patients with a disease where corticosteroids are contraindicated, e.g. active gastric&#xD;
        or duodenal ulcer, or poorly controlled insulin dependent diabetes. Patients with&#xD;
        well-controlled insulin-dependent diabetes mellitus may be considered, providing they&#xD;
        understand their glucose levels will increase, and their insulin dose will require&#xD;
        adjusting.&#xD;
&#xD;
        J. Because no dosing or adverse event data are currently available on the use of&#xD;
        satraplatin in patients less than 18 years of age, children are excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L Dahut, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology and Hematology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0074.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000 Jun;163(6):1632-42. Review.</citation>
    <PMID>10799151</PMID>
  </reference>
  <reference>
    <citation>Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005 Feb 1;23(4):826-31.</citation>
    <PMID>15681527</PMID>
  </reference>
  <reference>
    <citation>Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998 Dec;160(6 Pt 2):2428-34.</citation>
    <PMID>9817397</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>February 27, 2013</results_first_submitted>
  <results_first_submitted_qc>February 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2013</results_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>William Dahut Jr., M.D.</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Gene Polymorphisms</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Satraplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT00634647/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Satraplatin</title>
          <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>death on study</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>declined to participate before treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Satraplatin</title>
          <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.83" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival.</title>
        <description>Time between the start of therapy and progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progressive Disease is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>15 months</time_frame>
        <population>24 pts were enrolled but only 21/24 were assessed for OS. One pt died on treatment and (e.g.3 pts were non-evaluable for analysis of response).</population>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin</title>
            <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival.</title>
          <description>Time between the start of therapy and progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progressive Disease is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>24 pts were enrolled but only 21/24 were assessed for OS. One pt died on treatment and (e.g.3 pts were non-evaluable for analysis of response).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 57 months.</time_frame>
        <population>The time frame for adverse events includes one year follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin</title>
            <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <population>The time frame for adverse events includes one year follow-up data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival (OS)</title>
        <description>Overall Survival is the time between the first day of treatment to the day of death.</description>
        <time_frame>time between the first day of treatment to the day of death, approximately 15.7 months</time_frame>
        <population>24 pts were enrolled but only 21/24 were assessed for OS. One pt died on treatment and (e.g.3 pts were non-evaluable for analysis of response).</population>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin</title>
            <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival (OS)</title>
          <description>Overall Survival is the time between the first day of treatment to the day of death.</description>
          <population>24 pts were enrolled but only 21/24 were assessed for OS. One pt died on treatment and (e.g.3 pts were non-evaluable for analysis of response).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="6.5" upper_limit="NA">The upper limit of the confidence interval was not reached because patients were on-study at the time data was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 57 months.</time_frame>
      <desc>The time frame for adverse events includes one year follow-up data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Satraplatin</title>
          <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>2 patients died from progressive disease and 8 died in follow-up from progressive disease.</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Other (septic shock)</sub_title>
                <description>patient died from septic shock</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="51" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual-Other, visual field deficit (blind spot)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dental: periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (pain intermittent diarrhea)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)::oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain-abdomen NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>(in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain -Other,intermittent LE pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder tract NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT/SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>AST/SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-Other, muscle cramping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain::Back</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain::Extremity-limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neuropathy:sensory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify)</sub_title>
                <description>left ear &quot;blk lesion&quot; papular flat; rashes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Dahut</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-435-8183</phone>
      <email>dahutw@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

